The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
New insights into the activities and toxicities of the old anticancer drug doxorubicin
Open accessAbstract
The anthracycline drug doxorubicin is among the most used—and useful—chemotherapeutics. While doxorubicin is highly effective in the treatment of various hematopoietic malignancies and solid tumours, its application is limited by severe adverse effects, including irreversible cardiotoxicity, therapy‐related malignancies and gonadotoxicity. This continues to motivate investigation into the mechanisms of anthracycline activities and toxicities, with the aim to overcome the latter without sacrificing the former. It has long been appreciated that doxorubicin causes DNA double‐strand breaks due to poisoning topoisomerase II. More recently, it became clear that doxorubicin also leads to chromatin damage achieved through eviction of histones from select sites in the genome. Evaluation of these activities in various anthracycline analogues has revealed that chromatin damage makes a major contribution to the efficacy of anthracycline drugs. Furthermore, the DNA‐damaging effect conspires with chromatin damage to cause a number of adverse effects. Structure–activity relationships within the anthracycline family offer opportunities for chemical separation of these activities towards development of effective analogues with limited adverse effects. In this review, we elaborate on our current understanding of the different activities of doxorubicin and their contributions to drug efficacy and side effects. We then offer our perspective on how the activities of this old anticancer drug can be amended in new ways to benefit cancer patients, by providing effective treatment with improved quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal structure of the nucleosome core particle at 2.8 Å resolution
Luger, K., Mäder, A. W., Richmond, R. K., Sargent, D. F., & Richmond, T. J. (1997) · Nature · doi:10.1038/38444 · Cited by 9,466
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003) · Cancer · doi:10.1002/cncr.11407 · Cited by 2,313
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L.-S., Lyu, Y. L., Liu, L. F., & Yeh, E. T. H. (2012) · Nature Medicine · doi:10.1038/nm.2919 · Cited by 1,948
DNA TOPOISOMERASE POISONS AS ANTITUMOR DRUGS
Liu, L. F. (1989) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.58.070189.002031 · Cited by 1,811
Targeting DNA topoisomerase II in cancer chemotherapy
Nitiss, J. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2607 · Cited by 1,791
Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies
Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,634
A clinicopathologic analysis of adriamycin cardiotoxicity
Lefrak, E. A., Piťha, J., Rosenheim, S., & Gottlieb, J. A. (1973) · Cancer · doi:10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2 · Cited by 1,560
ESHRE Guideline: management of women with premature ovarian insufficiency
(2016) · Human Reproduction · doi:10.1093/humrep/dew027 · Cited by 1,555
Adriamycin-Induced DNA Damage Mediated by Mammalian DNA Topoisomerase II
Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D., & Liu, L. F. (1984) · Science · doi:10.1126/science.6093249 · Cited by 1,538
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512
Estey, E., & Döhner, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69780-8 · Cited by 1,296
Adriamycin: The Role of Lipid Peroxidation in Cardiac Toxicity and Tumor Response
Myers, C. E., McGuire, W. P., Liss, R. H., Ifrim, I., Grotzinger, K., & Young, R. C. (1977) · Science · doi:10.1126/science.877547 · Cited by 1,111
Roles of eukaryotic topoisomerases in transcription, replication and genomic stability
Pommier, Y., Sun, Y., Huang, S.-Y. N., & Nitiss, J. L. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.111 · Cited by 950
Voorwerk, L., Slagter, M., Horlings, H. M., Sikorska, K., van de Vijver, K. K., de Maaker, M., Nederlof, I., Kluin, R. J. C., Warren, S., Ong, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0432-4 · Cited by 905
Tewey, K. M., Chen, G. L., Nelson, E. M., & Liu, L. F. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)47282-6 · Cited by 887
DNA topoisomerase II and its growing repertoire of biological functions
Nitiss, J. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2608 · Cited by 885
Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42.
(1987) · PubMed · Cited by 851
Smith, L. A., Cornelius, V. R., Plummer, C. J., Levitt, G., Verrill, M., Canney, P., & Jones, A. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-337 · Cited by 753
Anthracycline-Induced Cardiotoxicity
Shan, K., Lincoff, A. M., & Young, J. B. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00008 · Cited by 749
Davies, K. J., & Doroshow, J. H. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35746-0 · Cited by 631
Adriamycin, 14‐hydroxydaimomycin, a new antitumor antibiotic from S. Peucetius var. caesius
Arcamone, F., Cassinelli, G., Fantini, G., Grein, A., Orezzi, P., Pol, C., & Spalla, C. (1969) · Biotechnology and Bioengineering · doi:10.1002/bit.260110607 · Cited by 622
Chromosome translocations and covert leukemic clones are generated during normal fetal development
Mori, H., Colman, S. M., Xiao, Z., Ford, A. M., Healy, L. E., Donaldson, C., Hows, J. M., Navarrete, C., & Greaves, M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.112218799 · Cited by 615
Lyu, Y. L., Kerrigan, J. E., Lin, C.-P., Azarova, A. M., Tsai, Y.-C., Ban, Y., & Liu, L. F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1649 · Cited by 612
Oxidative stress injury in doxorubicin-induced cardiotoxicity
Songbo, M., Lang, H., Xinyong, C., Bin, X., Ping, Z., & Liang, S. (2019) · Toxicology Letters · doi:10.1016/j.toxlet.2019.02.013 · Cited by 566
Molecular mechanisms of ATP secretion during immunogenic cell death
Martins, I., Wang, Y., Michaud, M., Ma, Y., Sukkurwala, A. Q., Shen, S., Kepp, O., Métivier, D., Galluzzi, L., Perfettini, J.-L., et al. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.75 · Cited by 563
Doroshow, J. H., & Davies, K. J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35747-2 · Cited by 540
Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide
Wu, C.-C., Li, T.-K., Farh, L., Lin, L.-Y., Lin, T.-S., Yu, Y.-J., Yen, T.-J., Chiang, C.-W., & Chan, N.-L. (2011) · Science · doi:10.1126/science.1204117 · Cited by 523
Harris, L., Batist, G., Belt, R., Rovira, D., Navari, R., Azarnia, N., Welles, L., Winer, E., & TLC D‐99 Study Group (2002) · Cancer · doi:10.1002/cncr.10201 · Cited by 512
Kayser, S., Döhner, K., Krauter, J., Köhne, C.-H., Horst, H. A., Held, G., von Lilienfeld-Toal, M., Wilhelm, S., Kündgen, A., Götze, K., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301713 · Cited by 487
Tan, C., Tasaka, H., Yu, K.-P., Murphy, M. L., & Karnofsky, D. A. (1967) · Cancer · doi:10.1002/1097-0142(1967)20:3<333::aid-cncr2820200302>3.0.co;2-k · Cited by 486
Lipshultz, S. E., Scully, R. E., Lipsitz, S. R., Sallan, S. E., Silverman, L. B., Miller, T. L., Barry, E. V., Asselin, B. L., Athale, U., Clavell, L. A., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70204-7 · Cited by 446
Early menopause in long-term survivors of cancer during adolescence
Byrne, J., Fears, T. R., Gail, M. H., Pee, D., Connelly, R. R., Austin, D. F., Holmes, G. F., Holmes, F. F., Latourette, H. B., Meigs, J. W., et al. (1992) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(92)91335-8 · Cited by 439
Barth, E. (1992) · Journal of Molecular and Cellular Cardiology · doi:10.1016/0022-2828(92)93381-s · Cited by 438
Pang, B., Qiao, X., Janssen, L., Velds, A., Groothuis, T., Kerkhoven, R., Nieuwland, M., Ovaa, H., Rottenberg, S., van Tellingen, O., et al. (2013) · Nature Communications · doi:10.1038/ncomms2921 · Cited by 420
Self-citationAlizadeh, D., Trad, M., Hanke, N. T., Larmonier, C. B., Janikashvili, N., Bonnotte, B., Katsanis, E., & Larmonier, N. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1545 · Cited by 416
Adriamycin-induced oxidative mitochondrial cardiotoxicity
Berthiaume, J. M., & Wallace, K. B. (2007) · Cell Biology and Toxicology · doi:10.1007/s10565-006-0140-y · Cited by 409
Wang, A. H. J., Ughetto, G., Quigley, G. J., & Rich, A. (1987) · Biochemistry · doi:10.1021/bi00378a025 · Cited by 405
Green, D. M., Whitton, J. A., Stovall, M., Mertens, A. C., Donaldson, S. S., Ruymann, F. B., Pendergrass, T. W., & Robison, L. L. (2002) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2002.126643 · Cited by 372
Review and Meta-Analysis of Incidence and Clinical Predictors of Anthracycline Cardiotoxicity
Lotrionte, M., Biondi-Zoccai, G., Abbate, A., Lanzetta, G., D'Ascenzo, F., Malavasi, V., Peruzzi, M., Frati, G., & Palazzoni, G. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.08.026 · Cited by 371
Perez, G. I., Knudson, C. M., Leykin, L., Korsmeyer, S. J., & Tilly, J. L. (1997) · Nature Medicine · doi:10.1038/nm1197-1228 · Cited by 353
Histone variants on the move: substrates for chromatin dynamics
Talbert, P. B., & Henikoff, S. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.148 · Cited by 347
Roca, J., & Wang, J. C. (1992) · Cell · doi:10.1016/0092-8674(92)90558-t · Cited by 317
Structural basis for gate-DNA recognition and bending by type IIA topoisomerases
Dong, K. C., & Berger, J. M. (2007) · Nature · doi:10.1038/nature06396 · Cited by 316
Anderson, R. A., Mitchell, R. T., Kelsey, T. W., Spears, N., Telfer, E. E., & Wallace, W. H. B. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00039-x · Cited by 293
DNA transport by a type II DNA topoisomerase: Evidence in favor of a two-gate mechanism
Roca, J., & Wang, J. C. (1994) · Cell · doi:10.1016/0092-8674(94)90222-4 · Cited by 288
DNA Topoisomerase II in Therapy-Related Acute Promyelocytic Leukemia
Mistry, A. R., Felix, C. A., Whitmarsh, R. J., Mason, A., Reiter, A., Cassinat, B., Parry, A., Walz, C., Wiemels, J. L., Segal, M. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042715 · Cited by 281
Mouse models of human AML accurately predict chemotherapy response
Zuber, J., Radtke, I., Pardee, T. S., Zhao, Z., Rappaport, A. R., Luo, W., McCurrach, M. E., Yang, M.-M., Dolan, M. E., Kogan, S. C., et al. (2009) · Genes & Development · doi:10.1101/gad.1771409 · Cited by 279
Drake, F., Zimmerman, J., McCabe, F., Bartus, H., Per, Sr., Sullivan, D., Ross, W., Mattern, M., Johnson, R., & Crooke, S. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)49317-9 · Cited by 277
Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors
Travis, L. B., Wahnefried, W. D., Allan, J. M., Wood, M. E., & Ng, A. K. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.41 · Cited by 264
Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists
Yamazaki, T., Hannani, D., Poirier-Colame, V, Ladoire, S., Locher, C., Sistigu, A., Prada, N., Adjemian, S., Catani, J. P., Freudenberg, M., et al. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.72 · Cited by 262
Antioxidants and Cancer Therapy: A Systematic Review
Ladas, E. J., Jacobson, J. S., Kennedy, D. D., Teel, K., Fleischauer, A., & Kelly, K. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.086 · Cited by 260
Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis
Green, P. S., & Leeuwenburgh, C. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(02)00144-8 · Cited by 252
Teepen, J. C., van Leeuwen, F. E., Tissing, W. J., van Dulmen-den Broeder, E., van den Heuvel-Eibrink, M. M., van der Pal, H. J., Loonen, J. J., Bresters, D., Versluys, B., Neggers, S. J. C. M. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6902 · Cited by 222
Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis
Wallace, K. B. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0008-2 · Cited by 221
Le Deley, M.-C., Leblanc, T., Shamsaldin, A., Raquin, M.-A., Lacour, B., Sommelet, D., Chompret, A., Cayuela, J.-M., Bayle, C., Bernheim, A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.100 · Cited by 216
Therapy-Related Acute Promyelocytic Leukemia
Beaumont, M., Sanz, M., Carli, P. M., Maloisel, F., Thomas, X., Detourmignies, L., Guerci, A., Gratecos, N., Rayon, C., San Miguel, J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.072 · Cited by 215
Role of iron in anthracycline cardiotoxicity: new tunes for an old song?
MINOTTI, G., CAIRO, G., & MONTI, E. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.2.199 · Cited by 214
Pendleton, M., Lindsey, R. H., Felix, C. A., Grimwade, D., & Osheroff, N. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12358 · Cited by 203
Secondary Sarcomas in Childhood Cancer Survivors: A Report From the Childhood Cancer Survivor Study
Henderson, T. O., Whitton, J., Stovall, M., Mertens, A. C., Mitby, P., Friedman, D., Strong, L. C., Hammond, S., Neglia, J. P., Meadows, A. T., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk052 · Cited by 200
Praga, C., Bergh, J., Bliss, J., Bonneterre, J., Cesana, B., Coombes, R. C., Fargeot, P., Folin, A., Fumoleau, P., Giuliani, R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.029 · Cited by 187
Stanulla, M., Wang, J., Chervinsky, D. S., Thandla, S., & Aplan, P. D. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.7.4070 · Cited by 178
Licata, S., Saponiero, A., Mordente, A., & Minotti, G. (2000) · Chemical Research in Toxicology · doi:10.1021/tx000013q · Cited by 176
Doxorubicin-induced ovarian toxicity
Ben‐Aharon, I., Bar‐Joseph, H., Tzarfaty, G., Kuchinsky, L., Rizel, S., Stemmer, S. M., & Shalgi, R. (2010) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-8-20 · Cited by 172
The role of iron in anthracycline cardiotoxicity
Gammella, E., Maccarinelli, F., Buratti, P., Recalcati, S., & Cairo, G. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00025 · Cited by 163
Vaage, J., Barberá‐Guillem, E., Abra, R. M., Huang, A., & Working, P. K. (1994) · Cancer · Cited by 162
Jakovcevski, M., Ruan, H., Shen, E. Y., Dincer, A., Javidfar, B., Ma, Q., Peter, C. J., Cheung, I., Mitchell, A. C., Jiang, Y., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.3004-14.2015 · Cited by 161
Uncoupling DNA damage from chromatin damage to detoxify doxorubicin
Qiao, X., van der Zanden, S. Y., Wander, D. P. A., Borràs, D. M., Song, J.-Y., Li, X., van Duikeren, S., van Gils, N., Rutten, A., van Herwaarden, T., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922072117 · Cited by 161
Self-citationOocyte DNA damage quality control requires consecutive interplay of CHK2 and CK1 to activate p63
Tuppi, M., Kehrloesser, S., Coutandin, D. W., Rossi, V., Luh, L. M., Strubel, A., Hötte, K., Hoffmeister, M., Schäfer, B., De Oliveira, T., et al. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0035-7 · Cited by 160
Hou, M., Chrysis, D., Nurmio, M., Parvinen, M., Eksborg, S., Söder, O., & Jahnukainen, K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2004 · Cited by 152
Delessard, M., Saulnier, J., Rives‐Feraille, A., Dumont, L., Rondanino, C., & Rives, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041454 · Cited by 151
Deley, M. L., Suzan, F., Cutuli, B., Delaloge, S., Shamsaldin, A., Linassier, C., Clisant, S., de Vathaire, F., Fenaux, P., & Hill, C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9048 · Cited by 150
Topoisomerase II and the etiology of chromosomal translocations
Felix, C. A., Kolaris, C. P., & Osheroff, N. (2006) · DNA repair · doi:10.1016/j.dnarep.2006.05.031 · Cited by 145
Substrate and product specificities of SET domain methyltransferases
Rizzo, P. A. D., & Trievel, R. C. (2011) · Epigenetics · doi:10.4161/epi.6.9.16069 · Cited by 136
Jones, R. L., Swanton, C., & Ewer, M. S. (2006) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.6.791 · Cited by 132
Henderson, T. O., Rajaraman, P., Stovall, M. A., Constine, L. S., Olive, A. M., Smith, S. A., Mertens, A. C., Meadows, A. T., Neglia, J. P., Hammond, S., et al. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.11.022 · Cited by 129
Mechanism of Generation of Therapy Related Leukemia in Response to Anti-Topoisomerase II Agents
Cowell, I. G., & Austin, C. A. (2012) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph9062075 · Cited by 129
Pommier, Y. G., Schwartz, R. E., Zwelling, L. A., & Kohn, K. W. (1985) · Biochemistry · doi:10.1021/bi00344a014 · Cited by 128
Chemotherapy and Thyroid Cancer Risk: A Report from the Childhood Cancer Survivor Study
Veiga, L. H. S., Bhatti, P., Ronckers, C. M., Sigurdson, A. J., Stovall, M., Smith, S. A., Weathers, R. E., Leisenring, W. M., Mertens, A. C., Hammond, S., et al. (2012) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0576 · Cited by 125
Molecular mechanism and binding free energy of doxorubicin intercalation in DNA
Jawad, B., Poudel, L., Podgornik, R., Steinmetz, N. F., & Ching, W. Y. (2019) · Physical Chemistry Chemical Physics · doi:10.1039/c8cp06776g · Cited by 125
Diamandidou, E., Buzdar, A. U., Smith, T. L., Frye, D., Witjaksono, M. A., & Hortobágyi, G. N. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2722 · Cited by 122
Doxorubicin Enhances Nucleosome Turnover around Promoters
Yang, F., Kemp, C. J., & Henikoff, S. (2013) · Current Biology · doi:10.1016/j.cub.2013.03.043 · Cited by 122
The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin
Hasinoff, B. B., Patel, D., & Wu, X. (2003) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2003.08.005 · Cited by 115
Yu, X., Ruan, Y., Huang, X., Dou, L., Lan, M., Cui, J., Chen, B., Gong, H., Wang, Q., Yan, M., et al. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.12.027 · Cited by 106
Betti, C. J., Villalobos, M. J., Díaz, M. O., & Vaughan, A. T. (2001) · PubMed · Cited by 99
Doxorubicin-induced apoptosis in germinal vesicle (GV) oocytes
Bar‐Joseph, H., Ben‐Aharon, I., Rizel, S., Stemmer, S. M., Tzabari, M., & Shalgi, R. (2010) · Reproductive Toxicology · doi:10.1016/j.reprotox.2010.07.003 · Cited by 96
Chemical profiling of the genome with anti-cancer drugs defines target specificities
Pang, B., de Jong, J., Qiao, X., Wessels, L. F. A., & Neefjes, J. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1811 · Cited by 92
Self-citationPerego, P., Corna, E., Cesare, M. D., Gatti, L., Polizzi, D., Pratesi, G., Supino, R., & Zunino, F. (2001) · Current Medicinal Chemistry · doi:10.2174/0929867013373994 · Cited by 91
Lai, J.-J., Cruz, F. M., & Rock, K. L. (2020) · Immunity · doi:10.1016/j.immuni.2019.11.013 · Cited by 85
Apoptotic stimuli initiate MLL-AF9 translocations that are transcribed in cells capable of division.
Betti, C. J., Villalobos, M. J., Dı́az, M. O., & Vaughan, A. T. (2003) · PubMed · Cited by 73
Cabanes, A., Tzemach, D., Goren, D., et al. (1998) · PubMed · Cited by 68
Current knowledge and future research directions in treatment-related second primary malignancies
Morton, L. M., Swerdlow, A. J., Schaapveld, M., Ramadan, S. M., Hodgson, D. C., Radford, J. A., & van Leeuwen, F. E. (2014) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2014.05.001 · Cited by 63
MLL1 and MLL1 fusion proteins have distinct functions in regulating leukemic transcription program
Xu, J., Li, L., Xiong, J., denDekker, A., Ye, A., Karatas, H., Liu, L., Wang, H., Qin, Z., Wang, S.-M., et al. (2016) · Cell Discovery · doi:10.1038/celldisc.2016.8 · Cited by 56
Chromatin Replication and Histone Dynamics
Alabert, C., Jasencakova, Z., & Groth, A. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6955-0_15 · Cited by 54
Schmidt, J. K., Roti, E. C. R., Ringelstetter, A. K., Khatib, H., Abbott, D. H., & Salih, S. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142588 · Cited by 46
Etoposide-related acute promyelocytic leukemia
Kudo, K., Yoshida, H., Kiyoi, H., Numata, S., Horibe, K., & Naoe, T. (1998) · Leukemia · doi:10.1038/sj.leu.2401089 · Cited by 43
Bäsecke, J., Cepek, L., Mannhalter, C., Krauter, J., Hildenhagen, S., Brittinger, G., Trümper, L. H. P., & Griesinger, F. (2002) · Blood · doi:10.1182/blood-2002-06-1673 · Cited by 41
JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML
Schnittger, S., Bacher, U., Kern, W., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404465 · Cited by 36
In vitro study of doxorubicin-induced oxidative stress in spermatogonia and immature Sertoli cells
Tremblay, A., & Delbès, G. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.04.014 · Cited by 36
Hasinoff, B. B., & Kala, S. V. (1993) · Inflammation Research · doi:10.1007/bf01975717 · Cited by 20
van Leeuwen, F. E., & Ronckers, C. M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.0465 · Cited by 19
Schaefer, A., Westendorf, J., Lingelbach, K. R., Schmidt, C. A., Mihalache, D.-L., Reymann, A., & Marquardt, H. (1993) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685675 · Cited by 14
Cited by
Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
Kciuk, M., Gielecińska, A., Mujwar, S., Kołat, D., Kałuzińska-Kołat, Ż., Celik, I., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040659 · Cited by 810
Chemotherapy Side-Effects: Not All DNA Damage Is Equal
van den Boogaard, W. M. C., Komninos, D. S. J., & Vermeij, W. P. (2022) · Cancers · doi:10.3390/cancers14030627 · Cited by 458
Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming
Mattioli, R., Ilari, A., Colotti, B., Mosca, L., Fazi, F., & Colotti, G. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101205 · Cited by 294
Natural and synthetic compounds in Ovarian Cancer: A focus on NRF2/KEAP1 pathway
Tossetta, G., & Marzioni, D. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106365 · Cited by 115
Increased cellular senescence in doxorubicin-induced murine ovarian injury: effect of senolytics
Gao, Y., Wu, T., Tang, X., Wen, J., Zhang, Y., Zhang, J., & Wang, S. (2023) · GeroScience · doi:10.1007/s11357-023-00728-2 · Cited by 56
Metadata
- Authors
- van der Zanden, S. Y., Qiao, X., & Neefjes, J.
- Venue
- The FEBS Journal
- Publisher
- Wiley
- Published
- 2020-10-19
- Volume
- 288
- Issue
- 21
- Pages
- 6095-6111
- ISSN
- 1742-464X (ISSN-L)
- 1742-4658
- OpenAlex
- W3091905208
- Cited by
- 410
- References
- 105
- FWCI
- 10.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.